FGF2 and neoplasm: IMiDs such as lenalidomide have been shown to promote their anti-angiogenic effects by inhibiting the production of VEGF and bFGF and block the pro-survival crosstalk between endothelial and tumor cells, thus, inhibiting tumor growth [87].